Jonaitis Erin M, Zetterberg Henrik, Koscik Rebecca Langhough, Betthauser Tobey J, Van Hulle Carol A, Hogan Kirk, Hegge Laura, Kollmorgen Gwendlyn, Suridjan Ivonne, Gleason Carey E, Engelman Corinne D, Okonkwo Ozioma C, Asthana Sanjay, Bendlin Barbara B, Carlsson Cynthia M, Johnson Sterling C, Blennow Kaj
School of Medicine and Public Health Wisconsin Alzheimer's Institute University of Wisconsin-Madison Madison Wisconsin USA.
Wisconsin Alzheimer's Disease Research Center School of Medicine and Public Health University of Wisconsin-Madison Madison Wisconsin USA.
Alzheimers Dement (Amst). 2022 Feb 9;14(1):e12266. doi: 10.1002/dad2.12266. eCollection 2022.
Blood-based Alzheimer's disease (AD) biomarkers show promise, but pre-analytical protocol differences may pose problems. We examined seven AD blood biomarkers (amyloid beta [ , , , total tau [t-tau], neurofilament light chain [NfL], and ) in three collection tube types (ethylenediaminetetraacetic acid [EDTA] plasma, heparin plasma, serum).
Plasma and serum were obtained from cerebrospinal fluid or amyloid positron emission tomography-positive and -negative participants (N = 38) in the Wisconsin Registry for Alzheimer's Prevention. We modeled AD biomarker values observed in EDTA plasma versus heparin plasma and serum, and assessed correspondence with brain amyloidosis.
Results suggested bias due to tube type, but crosswalks are possible for some analytes, with excellent model fit for NfL ( = 0.94), adequate for amyloid ( = 0.40-0.69), and weaker for t-tau ( = 0.04-0.42) and ( = 0.22-0.29). Brain amyloidosis differentiated several measures, especially EDTA plasma ( = 1.29).
AD biomarker concentrations vary by tube type. However, correlations for some biomarkers support harmonization across types, suggesting cautious optimism for use in banked blood.
基于血液的阿尔茨海默病（AD）生物标志物显示出前景，但分析前方案差异可能会带来问题。我们在三种采血管类型（乙二胺四乙酸[EDTA]血浆、肝素血浆、血清）中检测了七种AD血液生物标志物（淀粉样β蛋白[ 、 、 、总tau蛋白[t-tau]、神经丝轻链[NfL]、 和 ）。
从威斯康星州阿尔茨海默病预防登记处的脑脊液或淀粉样正电子发射断层扫描阳性和阴性参与者（N = 38）中获取血浆和血清。我们对在EDTA血浆与肝素血浆及血清中观察到的AD生物标志物值进行建模，并评估与脑淀粉样变性的对应关系。
结果表明存在因采血管类型导致的偏差，但某些分析物可以建立转换关系，NfL的模型拟合良好（ = 0.94），淀粉样蛋白的拟合程度适中（ = 0.40 - 0.69），t-tau和 的拟合较弱（ = 0.04 - 0.42和 = 0.22 - 0.29）。脑淀粉样变性区分了几种测量指标，尤其是EDTA血浆 （ = 1.29）。
AD生物标志物浓度因采血管类型而异。然而，一些生物标志物的相关性支持不同类型之间的统一，这表明对用于储存血液的检测持谨慎乐观态度。
